Investors sold shares of Bioverativ Inc (NASDAQ:BIVV) on strength during trading on Thursday. $33.30 million flowed into the stock on the tick-up and $65.07 million flowed out of the stock on the tick-down, for a money net flow of $31.77 million out of the stock. Of all equities tracked, Bioverativ had the 0th highest net out-flow for the day. Bioverativ traded up $0.46 for the day and closed at $103.52
A number of brokerages recently commented on BIVV. Credit Suisse Group restated a “neutral” rating on shares of Bioverativ in a research note on Wednesday, January 24th. Argus reiterated a “hold” rating on shares of Bioverativ in a research note on Wednesday, January 24th. Zacks Investment Research cut shares of Bioverativ from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Morgan Stanley reiterated an “underweight” rating and issued a $47.00 target price (up from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $71.00 target price on shares of Bioverativ in a research note on Monday, October 23rd. Thirteen equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $62.86.
Several large investors have recently modified their holdings of the company. Wells Fargo & Company MN bought a new position in shares of Bioverativ in the 3rd quarter worth $124,500,000. Woodford Investment Management Ltd bought a new position in shares of Bioverativ in the 3rd quarter worth $85,455,000. Jackson Square Partners LLC bought a new position in shares of Bioverativ in the 3rd quarter worth $99,336,000. Old Mutual Global Investors UK Ltd. bought a new position in shares of Bioverativ in the 3rd quarter worth $96,827,000. Finally, ValueAct Holdings L.P. bought a new position in shares of Bioverativ in the 3rd quarter worth $72,514,000. 95.56% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/03/investors-sell-shares-of-bioverativ-bivv-on-strength-bivv.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.